Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19

NCT07279766 is registered in ClinicalTrials.gov with Tor Biering-Sørensen as lead sponsor.

NCT NCT07279766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07279766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19
Lead sponsor
Tor Biering-Sørensen
Phase
Phase 4
Overall status
Completed
Start date
December 11, 2025
Completion date
September 5, 2026
Enrollment
41,060 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19